How could nuciferine affect sleep architecture (REM/alpha) based on mechanism?

Nuciferine's receptor profile predicts a REM-suppressing, arousal-shifting drug, but nobody has recorded sleep in a person taking it.

Nuciferine is not a sedative in the way tea sellers claim. In lab assays it binds 5-HT2A and 5-HT2C as an antagonist and 5-HT7 as an inverse agonist, with weaker partial agonism at dopamine D2 [4]. That profile is close to an atypical antipsychotic. Antipsychotics of that class suppress REM: longer REM latency, less REM duration and density [2]. So the honest prediction is fewer REM minutes, not more. Alpha activity is a separate lever. Alpha rhythms and sleep spindles are built by thalamocortical GABA signaling, and losing the alpha1 subunit of the GABA-A receptor sharpened spindles and cut waking alpha power [5]. Nuciferine does not appear to act on GABA-A in these records, so alpha should shift only indirectly, through whatever it does to arousal.

REM and NREM are run by separate machinery, with REM tracking cholinergic and monoaminergic balance rather than total sleep time [1][2]. That matters: a drug can leave total sleep untouched and still cut REM. Its vasorelaxant, calcium-channel-blocking action on rat arteries [3] tells you nothing reliable about brain sleep circuits.

Nobody has measured REM latency or alpha power in a person taking nuciferine. That study, a polysomnogram against placebo at a known dose, is the one that would settle it.

My call: expect REM suppression and little direct alpha change, from receptor pharmacology alone. Confidence: low, since this is inference from a receptor table, not sleep recordings.